| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
5,448 |
4,824 |
$363K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
5,760 |
5,167 |
$323K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
2,850 |
2,181 |
$301K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
3,940 |
3,465 |
$199K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
3,673 |
3,146 |
$161K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
2,578 |
2,265 |
$155K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
3,273 |
2,887 |
$155K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
2,248 |
1,777 |
$143K |
| 80053 |
Comprehensive metabolic panel |
5,778 |
4,710 |
$122K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
924 |
797 |
$85K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
1,864 |
1,591 |
$81K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
1,351 |
1,219 |
$60K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
1,398 |
1,289 |
$56K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
2,027 |
1,665 |
$44K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
6,296 |
5,149 |
$34K |
| 81001 |
|
3,510 |
2,979 |
$34K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
480 |
415 |
$33K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
558 |
377 |
$32K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
495 |
446 |
$27K |
| 70450 |
Computed tomography, head or brain; without contrast material |
473 |
422 |
$26K |
| 84703 |
|
2,450 |
2,102 |
$25K |
| 87081 |
|
762 |
673 |
$25K |
| 87088 |
|
3,419 |
2,907 |
$24K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
671 |
484 |
$22K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
796 |
720 |
$19K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
175 |
161 |
$17K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
264 |
246 |
$15K |
| 82962 |
|
1,447 |
966 |
$15K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
889 |
790 |
$15K |
| 81003 |
|
1,923 |
1,672 |
$15K |
| 84484 |
|
1,851 |
1,500 |
$14K |
| 83605 |
|
1,176 |
947 |
$10K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
1,508 |
651 |
$9K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
64 |
63 |
$9K |
| 82948 |
|
511 |
367 |
$9K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
1,401 |
1,180 |
$8K |
| 83690 |
|
1,652 |
1,392 |
$8K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
205 |
107 |
$8K |
| 85027 |
|
1,585 |
1,241 |
$7K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
89 |
79 |
$7K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
105 |
99 |
$6K |
| 87186 |
|
808 |
641 |
$5K |
| 71046 |
Radiologic examination, chest; 2 views |
1,722 |
1,503 |
$4K |
| 84443 |
Thyroid stimulating hormone (TSH) |
383 |
325 |
$4K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
12 |
12 |
$4K |
| 87077 |
|
787 |
632 |
$4K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
78 |
73 |
$4K |
| 83735 |
|
955 |
666 |
$4K |
| 80306 |
|
249 |
215 |
$3K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
43 |
40 |
$3K |
| 85610 |
|
752 |
596 |
$3K |
| 73610 |
|
559 |
408 |
$2K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
55 |
41 |
$2K |
| 88720 |
|
26 |
24 |
$2K |
| 85379 |
|
364 |
301 |
$2K |
| 84145 |
|
118 |
105 |
$2K |
| 73630 |
|
320 |
261 |
$2K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
3,020 |
2,465 |
$1K |
| 83880 |
|
62 |
53 |
$1K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
2,993 |
2,404 |
$1K |
| 0012A |
|
53 |
52 |
$1K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,296 |
1,120 |
$1K |
| 76830 |
Ultrasound, transvaginal |
26 |
24 |
$989.44 |
| 0011A |
|
52 |
52 |
$956.82 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
152 |
137 |
$841.75 |
| 71045 |
Radiologic examination, chest; single view |
1,124 |
958 |
$840.78 |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
95 |
79 |
$780.41 |
| G0382 |
Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) |
58 |
50 |
$778.98 |
| 36415 |
Collection of venous blood by venipuncture |
5,787 |
4,493 |
$687.61 |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
43 |
40 |
$671.76 |
| 86140 |
|
67 |
51 |
$473.83 |
| 85730 |
|
109 |
96 |
$397.44 |
| 80320 |
|
155 |
126 |
$380.71 |
| 96375 |
Therapeutic injection; each additional sequential IV push |
2,264 |
1,832 |
$340.05 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
73 |
68 |
$324.82 |
| G0381 |
Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) |
13 |
13 |
$259.73 |
| 0064A |
|
23 |
13 |
$180.48 |
| 29799 |
|
16 |
14 |
$127.32 |
| 73502 |
|
80 |
61 |
$125.94 |
| 80061 |
Lipid panel |
13 |
12 |
$95.08 |
| 97161 |
|
12 |
12 |
$82.33 |
| 73030 |
|
39 |
30 |
$65.24 |
| 87210 |
|
15 |
12 |
$48.00 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
1,290 |
1,130 |
$22.64 |
| J2704 |
Injection, propofol, 10 mg |
2,022 |
1,405 |
$8.24 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
4,195 |
2,994 |
$5.33 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
404 |
349 |
$4.59 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
3,015 |
2,389 |
$3.65 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
1,714 |
1,217 |
$1.97 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
1,666 |
1,276 |
$1.57 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,347 |
1,142 |
$1.11 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
2,115 |
1,706 |
$0.37 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
3,418 |
2,625 |
$0.36 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
864 |
631 |
$0.00 |
| A9270 |
Non-covered item or service |
390 |
217 |
$0.00 |
| 73560 |
|
30 |
24 |
$0.00 |
| J2795 |
Injection, ropivacaine hydrochloride, 1 mg |
24 |
13 |
$0.00 |
| 96376 |
|
47 |
38 |
$0.00 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
14 |
12 |
$0.00 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
14 |
13 |
$0.00 |
| J7699 |
Noc drugs, inhalation solution administered through dme |
12 |
12 |
$0.00 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
200 |
148 |
$0.00 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
26 |
24 |
$0.00 |
| C1713 |
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) |
14 |
12 |
$0.00 |
| 73562 |
|
13 |
12 |
$0.00 |